BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 7526305)

  • 1. Maternal serum pregnancy-associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy.
    Brizot ML; Snijders RJ; Bersinger NA; Kuhn P; Nicolaides KH
    Obstet Gynecol; 1994 Dec; 84(6):918-22. PubMed ID: 7526305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
    Spencer K; Cowans NJ; Avgidou K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Oct; 28(5):637-43. PubMed ID: 16952214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
    Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
    Spencer K; Cowans NJ; Molina F; Kagan KO; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Feb; 31(2):147-52. PubMed ID: 17992705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data.
    Merz E; Thode C; Alkier A; Eiben B; Hackelöer BJ; Hansmann M; Huesgen G; Kozlowski P; Pruggmaier M; Wellek S
    Ultraschall Med; 2008 Dec; 29(6):639-45. PubMed ID: 19085755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-trimester levels of pregnancy-associated plasma protein-A and free beta-hCG in pregnancies with trisomy 13.
    Spencer K; Crossley JA; Aitken DA; Nicolaides KH
    Prenat Diagn; 2005 May; 25(5):358-61. PubMed ID: 15906423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Valencia C; Maiz N; Nicolaides KH
    Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of birth weight by fetal crown-rump length and maternal serum levels of pregnancy-associated plasma protein-A in the first trimester.
    Leung TY; Sahota DS; Chan LW; Law LW; Fung TY; Leung TN; Lau TK
    Ultrasound Obstet Gynecol; 2008 Jan; 31(1):10-4. PubMed ID: 18098339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy.
    Brizot ML; Snijders RJ; Butler J; Bersinger NA; Nicolaides KH
    Br J Obstet Gynaecol; 1995 Feb; 102(2):127-32. PubMed ID: 7538782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
    Spencer K; Cowans NJ; Avgidou K; Molina F; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jan; 31(1):15-9. PubMed ID: 17999381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.
    Bindra R; Heath V; Liao A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2002 Sep; 20(3):219-25. PubMed ID: 12230441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal serum placental protein 13 at eleven to thirteen weeks in chromosomally abnormal pregnancies.
    Akolekar R; Pérez Penco JM; Skyfta E; Rodríguez Calvo J; Nicolaides KH
    Fetal Diagn Ther; 2010; 27(2):72-7. PubMed ID: 20332643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
    Kagan KO; Anderson JM; Anwandter G; Neksasova K; Nicolaides KH
    Prenat Diagn; 2008 Dec; 28(13):1209-13. PubMed ID: 19039823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at 11-13+6 weeks of gestation.
    Kagan KO; Frisova V; Nicolaides KH; Spencer K
    Prenat Diagn; 2007 Sep; 27(9):849-53. PubMed ID: 17590888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.